Rta-IgG as a biomarker for diagnosis and post treatment prognostic of nasopharyngeal carcinoma
Rta-IgG as a biomarker for diagnosis and post treatment prognostic of nasopharyngeal carcinoma
复制标题
Rta-IgG作为鼻咽癌诊断和治疗后预后的生物标志物
DOI：
10.3233/cbm-160586
复制
发表时间：
2016-01-01
影响因子：
3.1
通讯作者：
Guo, Lin
中科院分区：
文献类型：
--
作者：
Xu, Xiao-Feng;Lu, Ren-Quan;Guo, Lin
背景技术背景：鼻咽癌（Nasopharyngeal carcinoma，NPC）是一种常见的头颈部恶性肿瘤。目的：检测未经治疗的NPC患者血清中EB病毒Rta蛋白的表达，并比较NPC患者血清中Rta-IgG和VCA-IgA的差异。在目前的工作中，收集13例未经治疗的鼻咽癌患者和10例非鼻咽癌对照的鼻咽组织进行免疫组化（IHC），染色分析Rta蛋白的表达水平，同时制备血清标本，采用酶联免疫吸附试验（ELISA）检测Rta-IgG水平对鼻咽癌患者、其他肿瘤患者及正常人的诊断价值。对26例鼻咽癌患者治疗前后及治疗后1 ~ 2年的血清Rta-IgG水平进行监测。Rta蛋白在鼻咽癌组和非鼻咽癌组中的表达差异有统计学意义（P < 0.05）。相应地，NPC患者血清Rta-IgG水平（3.05，1.19-4.95）明显高于非NPC参与者（0.15，0.08-0.30，P < 0.05）包括肺癌患者（0.14，0.08-0.19），乳腺癌患者（0.17，0.10-0.25），胃癌患者（0.08，0.05-0.16），恶性淋巴瘤患者鼻咽良性病变组（1.65，0.74-1.93）和健康志愿者组（0.22，0.13-0.32）。受试者操作特征（ROC）分析结果表明，Rta-IgG诊断鼻咽癌的敏感性为83.6%，特异性为82.4%，其诊断效率高于VCA-IgA。Rta-IgG阳性率与临床分期有关，与转移部位无关。结论：鼻咽癌患者血清Rta表达水平升高，血清Rta-IgG可作为鼻咽癌鉴别诊断和疗效监测的生物标志物。
BACKGROUND: Nasopharyngeal carcinoma (NPC) is a common type of head and neck cancer.OBJECTIVE: This study aimed to detect the expression of Epstein-Barr viral Rta protein in patients with untreated NPC, and compare the serum Rta-IgG with the VCA-IgA in patients with NPC.METHODS: In the current work, the nasopharyngeal tissues of untreated NPC patients (n = 13) and non-NPC controls (n = 10) were collected for the immunohistochemical (IHC) staining to analyze the levels of Rta protein expression, meanwhile serum samples from the participants were prepared to assess the roles of Rta-IgG level with Enzyme-linked immunosorbence assay (ELISA) in diagnosis of NPC including the patients with NPC, the patients with other cancers, and normal volunteers.RESULTS: The levels of serum Rta-IgG in 26 NPC patients were monitored at pre-and post-treatments, as well as one to two year after. We found that there was a significant difference of the expression levels of Rta protein between NPC and non-NPC groups (P < 0.05). Correspondingly, the levels of serum Rta-IgG in NPC patients (3.05, 1.19-4.95) were significantly higher than those of non-NPC participants (0.15, 0.08-0.30, P < 0.05) including the patients with lung cancer (0.14, 0.08-0.19), the patients with breast carcinoma (0.17, 0.10-0.25), the patients with gastric carcinoma (0.08, 0.05-0.16), the patients with malignant lymphoma (0.13, 0.08-0.20), the patients with benign nasopharyngeal disease (1.65, 0.74-1.93) and healthy volunteers (0.22, 0.13-0.32), respectively. With a receiver operation characteristic (ROC) analysis, the cut-off value to discriminate NPC patients from the controls was established at 0.92 (S/CO) for Rta-IgG (sensitivity 83.6%; specificity 82.4%), the diagnosis efficacy of Rta-IgG was higher than VCA-IgA. The positive rates of Rta-IgG were related to clinical stage, but not metastatic sites. Serum concentrations of Rta-IgG were decreased in NPC patients with effective radiation, and slightly raised or with no change with ineffective radiation.CONCLUSIONS: Rta expression levels are elevated in the patients with NPC, and serum Rta-IgG is a promising biomarker in both differential diagnosis and therapy-monitoring of the patients with NPC.